New hope for transplant patients: drug targets kidney protein leak

NCT ID NCT07219121

Ongoing Disease control Sponsor: Travere Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called sparsentan for people who have protein in their urine after a kidney transplant due to IgA nephropathy or FSGS. About 20 adults will take the drug once daily for 36 weeks to see if it safely reduces protein levels and protects kidney function. The goal is to better control the disease and improve long-term transplant health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

focal segmental glomerulosclerosis IgA glomerulonephritis kidney disorder proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOCAL SEGMENTAL GLOMERULOSCLEROSIS IMMUNOGLOBULIN A (IGA) NEPHROPATHY KIDNEY TRANSPLANT PROTEINURIA

Contacts and locations

Show contact details

Locations

Cornell Medical Center

New York, New York, 10065, United States
Dallas Nephrology Associates

Dallas, Texas, 75204, United States
Ohio State University

Columbus, Ohio, 43210, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
University of North Carolina Chapel Hill

Morrisville, North Carolina, 27560, United States
University of Texas

Galveston, Texas, 27599, United States
University of Washington

Seattle, Washington, 98195, United States
University of Wisconsin

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.